BioSpace News Archive

ObsEva SA announced a symposium and three oral presentations on linzagolix, an oral GnRH antagonist, at the 7th Society of Endometriosis and Uterine Disorders Congress being held virtually and in Stockholm, Sweden as a hybrid event from December 9-11, 2021.

Highlights include release of new “Kit 12" and R10.4 flow cells for >Q20 raw read and around Q30 Duplex sequencing accuracy, and the new PromethION P2 device, a palm-sized, high-throughput sequencer that delivers the most accessible low-cost, high-output Oxford Nanopore sequencer

Spago Nanomedical AB annouced that all patients have been recruited in the second dose group in the company’s ongoing clinical phase I study SPAGOPIX-01 with the tumor-selective contrast agent SpagoPix.

GO2 Foundation for Lung Cancer (GO2 Foundation) has hired Joelle Fathi , DNP to serve as Chief Healthcare Delivery Officer.

TScan Therapeutics, Inc. today announced that it has completed the construction of a state-of-the-art GMP manufacturing facility to manufacture Phase I/II TCR-T therapies.

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that a poster presentation sharing new clinical data from the ongoing SRF617 Phase 1 trial will be presented at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021.

Alpha Cognition Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, announced the appointment of Cedric O’Gorman, M.D., as the Company’s Chief Medical Officer.

Discovery Life Sciences™, the biospecimen and biomarker specialists™, announced that it has acquired In Vitro ADMET Laboratories to add the world’s largest hepatocyte inventory and a world-renowned scientific leader to its growing company.

Texas A&M University Health Science Center (Texas A&M Health) and Wave Neuroscience announced the second phase of their post-traumatic stress disorder (PTSD) clinical trial today.

India Globalization Capital, Inc. (IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1.